Related Experiment Video

Updated: Aug 25, 2025

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.3K

Role of Sirtuins in the Pathobiology of Onco-Hematological Diseases: A PROSPERO-Registered Study and In Silico

João Vitor Caetano Goes1,2, Luiz Gustavo Carvalho1,3, Roberta Taiane Germano de Oliveira1,4

  • 1Center for Research and Drug Development (NPDM), Federal University of Ceara, Fortaleza 60020-181, Ceará, Brazil.

Cancers
|October 14, 2022
PubMed

Insights

Sirtuins (SIRTs) influence aging and solid tumors. This study explores SIRTs

Area of Science:

  • * Hematology and Aging Research
  • * Molecular Biology and Cancer Pathogenesis
  • * Bioinformatics and Gene Expression Analysis

Background:

  • * Sirtuins (SIRTs) are key regulators of cellular and organismal aging.
  • * SIRTs' role in solid tumors is established, but their impact on hematopoietic aging and hematological cancers is understudied.
  • * Hematopoietic aging involves system failures that can lead to neoplasms.

Purpose of the Study:

  • * To systematically review and analyze the role of Sirtuins (SIRTs) in the pathogenesis and prognosis of hematological cancers.
  • * To investigate the link between hematopoietic aging, genomic instability, and the development of hematological malignancies.
  • * To highlight the need for further research into SIRT inhibition for cancer treatment.

Main Methods:

  • * Conducted a systematic review (PROSPERO #CRD42022310079).
  • * Performed in silico analysis using the GEPIA database for gene expression.
  • * Synthesized evidence on SIRTs' role in hematological cancer pathobiology.

Main Results:

  • * Sirtuin (SIRT) gene family members are implicated in aging processes.
  • * In silico analysis suggests SIRTs' involvement in the pathobiology of hematological malignancies, including leukemias, lymphomas, and myeloma.
  • * Evidence supports the role of SIRTs in the advancement of pathogenesis and/or prognosis in hematological cancers.

Conclusions:

  • * Sirtuins (SIRTs) are crucial in hematopoietic aging and the development of hematological neoplasms.
  • * Further research and clinical trials are needed to explore SIRT inhibition for controlling clonal progression in hematological cancers.
  • * SIRTs represent promising molecular targets for managing age-related hematopoietic system failures and associated cancers.
Keywords:
aging biomarkersonco-hematological disorderssirtuins

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K